Notes
Annual bleeding rate
Reference
McMullen S, et al. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States. Value in Health 20: 93-99, No. 1, Jan 2017. Available from: URL: http://doi.org/10.1016/j.jval.2016.09.2396
Rights and permissions
About this article
Cite this article
rFVIIIFc for haemophilia A has small societal cost in USA. PharmacoEcon Outcomes News 773, 32 (2017). https://doi.org/10.1007/s40274-017-3817-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3817-y